1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tianda Pharmaceuticals Ltd.

Tianda Pharmaceuticals Ltd.

HHKEX:455
0.09
HKD
0.00
(0.00%)
344.01MMarket Cap
Tianda Pharmaceuticals Ltd.
HKEX:455
(Hong Kong Exchange)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
TTM
HKD
0.07
0.05
0.1
0.13
0.07
0.09
0.09
0.17
0.25
0.23
0.22
0.24
- -
0.25
0.15
0.15
- -
Revenue per Share
0.04
0.02
0.02
0.01
-0.01
- -
0.01
- -
- -
- -
-0.01
-0.01
- -
-0.01
-0.03
-0.03
- -
Basic EPS, GAAP
0.03
0.03
0.06
0.02
-0.03
- -
0.02
0.02
-0.01
-0.06
-0.08
-0.03
- -
-0.05
-0.02
- -
- -
Free Cash Flow per Basic Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.36
0.38
0.39
0.4
0.39
0.38
0.36
0.39
0.36
0.34
0.35
0.35
0.29
0.28
0.24
0.21
0.24
Book Value per Share
0.29
0.37
0.28
0.3
0.29
0.3
0.3
0.27
0.28
0.28
0.29
0.29
0.24
0.22
0.16
0.14
0.16
Tangible Book Value per Share
1,555
1,870
1,870
1,870
1,870
2,050
2,151
2,151
2,150
2,150
2,150
2,150
2,150
2,150
2,150
2,150
2,150
Basic Weighted Avg Shares
104
97
180
247
139
193
196
362
527
491
474
510
- -
532
330
323
- -
Sales/Revenue/Turnover
57.02
53.01
30.99
24.98
-23.18
4.81
9.9
4.53
2.4
2
-6.58
-8.24
- -
-4.59
-15.17
-15.96
- -
Operating Margin (%)
11
24
19
18
19
21
25
22
16
20
21
22
- -
36
38
39
- -
Depreciation Expense
67
43
38
22
-18
7
12
10
3
3
-27
-20
- -
-24
-61
-70
- -
Net Income, GAAP
15.54
25.24
19.25
24.02
- -
27.45
24.42
25.98
38.92
44.75
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
65.05
44.3
20.94
8.92
-12.87
3.41
6.36
2.77
0.5
0.64
-5.72
-3.88
- -
-4.54
-18.6
-21.67
- -
Profit Margin (%)
587
404
394
432
391
411
417
482
542
449
392
306
196
31
-35
-41
-35
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
20
122
99
71
11
3
46
3
LT Debt
847
870
775
815
788
847
813
886
811
760
790
789
654
592
506
456
506
Total Equity
7.9
4.91
5.83
6.52
- -
1.36
2.23
1.29
0.88
0.47
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
5.1
0.77
0.95
-0.61
- -
-0.03
0.02
-0.25
-1.26
-0.29
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
12.42
6.25
5.24
2.96
-2.42
0.85
1.56
1.23
0.33
0.42
-3.67
-2.61
- -
-3.96
-11.18
-14.55
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
102
96
124
LT Borrowings
8
- -
- -
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,150
2,150
2,150
Market Capitalization
469
559
344

Working Capital

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
344
244
216
Cash, Cash Equivalents & STI
162
98
86
Accounts Receivable, Net
71
62
59
Inventories
65
73
40
Total Current Liabilities
313
253
251
Payables & Accruals
- -
- -
- -
ST Debt
102
96
124
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.69%
-10.22%
-9.75%
Free Cash Flow
- -
- -
-87.42%
Net Income, GAAP
- -
- -
14.06%
Sales/Revenue/Turnover
- -
- -
-2.12%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
532
2024
- -
- -
330
2025
- -
- -
323

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.03
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tianda Pharmaceuticals Limited (0455.HK) is an investment holding company engaged in the research, development, manufacture and sale of pharmaceutical, biotechnology and healthcare products primarily in Mainland China, Hong Kong and Australia. Founded in 1992 and headquartered in Central, Hong Kong, the company operates through three main segments including Pharmaceuticals and Medical Technologies, Chinese Medicine, and Medical and Healthcare Services; it offers a comprehensive product portfolio encompassing Chinese medicines such as ZhiKang Granules, chemical drugs including Tuoping Valsartan Capsules and Ai Sen Ao Aceglutamide for Injection, biological products like Zhentai Cerebroprotein Hydrolysate Injection and Gan Fu Xin Vinpocetine Injection, health products under the self-owned Herb Valley and Tuokang brands featuring Pu’er Tea Cream series and throat lozenges, medical appliances, as well as CDMO/CMO services and traditional Chinese medicine decoction pieces; therapeutic areas cover cardio-cerebrovascular, paediatric, anti-flu and respiratory, anti-infection, detoxification, anti-cancer and others, with distribution through nationwide marketing networks, retailers and subsidiaries in key regions. A subsidiary of Tianda Group Limited, the company maintains R&D centres and production bases in Zhuhai and Kunming that hold GMP certifications from Chinese and Australian authorities, alongside marketing centres in Shenzhen and Sydney. Recent developments include the launch of four new products in 2024 covering respiratory, hypertension and paediatric asthma areas such as Ibuprofen Suspension, Nicorandil for Injection and Metformin Hydrochloride and Empagliflozin Tablets; completion of two CDE registration applications and advancement of three ongoing projects alongside re-registration of two core products, bringing CDMO/CMO offerings to 12 products; operational startup of Tianda Chinese Medicine (Bozhou) Ltd in late 2024 to bolster the TCM supply chain with authentic medicinal materials like earthworm and safflower; opening of the Jordan TDMall clinic in Hong Kong in October 2024 as an oncology treatment centre under the TDMall brand; positive Phase II clinical trial results for Baoxin Granules in treating chronic heart failure with preparation for Phase III; board changes in 2025 appointing Mr. Zhu Haomiao as non-executive director, Mr. Lam Yat Fai as lead independent non-executive director and Dr. Xian Yanfang to the nomination committee; and strategic deepening of client cooperation while expanding e-commerce, OTC and third-terminal channels amid national procurement adaptations.